Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.56 |
| ▸ | GNPAT | O15228 | 1/20 | 0.54 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.53 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.50 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29692934 | 0.97 | ERAP2 (0.57) | NAALAD2GNPATERAP2LNPEPLTA4H | |
| SCHEMBL29774693 | 0.94 | GNPAT (0.56) | NAALAD2GNPATERAP2LNPEPLTA4H | |
| SCHEMBL30099620 | 0.94 | GNPAT (0.56) | NAALAD2GNPATERAP2LNPEPLTA4H | |
| SCHEMBL30099583 | 0.94 | GNPAT (0.56) | NAALAD2GNPATERAP2LNPEPLTA4H | |
| SCHEMBL29774691 | 0.94 | GNPAT (0.56) | NAALAD2GNPATERAP2LNPEPLTA4H | |
| SCHEMBL30099615 | 0.94 | GNPAT (0.56) | NAALAD2GNPATERAP2LNPEPLTA4H | |
| SCHEMBL6237394 | 0.93 | NAALAD2 (0.64) | NAALAD2GNPATLTA4HPOLBFOLH1 | |
| SCHEMBL27652943 | 0.93 | NAALAD2 (0.64) | NAALAD2GNPATLTA4HPOLBFOLH1 | |
| SCHEMBL29406233 | 0.92 | ERAP2 (0.60) | GNPATERAP2LNPEPLTA4HMMP2 | |
| SCHEMBL29763133 | 0.92 | BACE1 (0.53) | NAALAD2GNPATERAP2LNPEPFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165282-A1 | CONFORMATIONAL CONSTRAINED SOMATOSTATIN RECEPTOR 3 PEPTIDE LIGANDS AND THEIR CONJUGATES AND USES THEREOF | STARGET PHARMA LTD. (IL) | 2024-05-23 | — | — | US | disclosed |
| CN-117042789-A | Conformationally constrained somatostatin receptor 3 peptide ligands, conjugates thereof and uses thereof | 斯塔吉特医药有限公司 | 2023-11-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165282-A1 | CONFORMATIONAL CONSTRAINED SOMATOSTATIN RECEPTOR 3 PEPTIDE LIGANDS AND THEIR CONJUGATES AND USES THEREOF | SSTR3, SSTR4, SSTR5 | NAALAD2 1123/4885GNPAT 2526/4885ERAP2 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.